JP2016529285A5 - - Google Patents

Info

Publication number

JP2016529285A5

JP2016529285A5 JP2016537859A JP2016537859A JP2016529285A5 JP 2016529285 A5 JP2016529285 A5 JP 2016529285A5 JP 2016537859 A JP2016537859 A JP 2016537859A JP 2016537859 A JP2016537859 A JP 2016537859A JP 2016529285 A5 JP2016529285 A5 JP 2016529285A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

cancer

inhibitor

tumor

compound

Prior art date

2014-08-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 27
• 239000003814 drug Substances 0.000 claims description 25
• 239000008194 pharmaceutical composition Substances 0.000 claims description 18
• 201000011510 cancer Diseases 0.000 claims description 16
• 150000001875 compounds Chemical class 0.000 claims description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
• 230000002062 proliferating effect Effects 0.000 claims description 10
• 239000003795 chemical substances by application Substances 0.000 claims description 8
• 201000010099 disease Diseases 0.000 claims description 8
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 6
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 6
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 6
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 6
• 239000003112 inhibitor Substances 0.000 claims description 6
• 206010029260 Neuroblastoma Diseases 0.000 claims description 5
• SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims description 4
• 101150023956 ALK gene Proteins 0.000 claims description 4
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
• 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 4
• 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims description 4
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 4
• 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 4
• 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 4
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 4
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 4
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 claims description 4
• 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 4
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
• 230000001419 dependent effect Effects 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 2
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
• 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims description 2
• 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• 206010025323 Lymphomas Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
• 230000003321 amplification Effects 0.000 claims description 2
• 208000035475 disorder Diseases 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 229940125436 dual inhibitor Drugs 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000037841 lung tumor Diseases 0.000 claims description 2
• 201000001441 melanoma Diseases 0.000 claims description 2
• 230000035772 mutation Effects 0.000 claims description 2
• 210000002569 neuron Anatomy 0.000 claims description 2
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
• 201000008968 osteosarcoma Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 208000023958 prostate neoplasm Diseases 0.000 claims description 2
• 208000013076 thyroid tumor Diseases 0.000 claims description 2
• 208000025421 tumor of uterus Diseases 0.000 claims description 2
• 206010046766 uterine cancer Diseases 0.000 claims description 2
• 230000002195 synergetic effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000001325 log-rank test Methods 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1